[New York, NY] — [February 24, 2026] — ObvioHealth, a global leader in digitalclinical trial solutions, today announced a strategic multi-trial licensingagreement with Novotech, a globallyrecognized full-service clinical research organization (CRO). Under theagreement, Novotech will license ObvioGo® across multiple clinical trials as astandardized participant-facing digital layer to support decentralized andhybrid study designs at scale.

ObvioGo is an enterprise platform for participant-facingtrial workflows, combining eConsent, ePRO/eCOA, and remote and hybridassessments in a single system. Under the multi-trial license, Novotech teamscan reuse standardized digital workflows across programs—accelerating studystart-up while maintaining consistency across regions and therapeutic areas.

“Standardization is becoming foundational to how clinicaltrials are delivered at scale,” said Ivan Jarry, CEO of ObvioHealth. “Thispartnership with Novotech builds on our existing relationship and reflects thatshift, reinforcing our focus on consistent, scalable digital execution acrossglobal programs.”

As decentralized and hybrid trials continue to evolve,sponsors need solutions that are both flexible and scalable,” saidMichael Stibilj, COO at Novotech. “By licensing ObvioGo across multiplestudies, we’re able to deliver adaptable, patient-centric tools that enhanceengagement, streamline trial participation, and support more efficient,consistent execution for sponsors and sites.

The agreement builds on the companies’ existing relationshipand deepens their shared focus on digitally enabled clinical trial delivery,reinforcing ObvioHealth’s role as a trusted enterprise technology partner andsupporting Novotech’s continued investment in scalable, sponsor-readydevelopment models.

About ObvioHealth

ObvioHealth is a global leader in digital clinical trialsolutions, delivering enterprise-grade technology to support decentralized,hybrid, and site-based studies. The ObvioGo® platform enables sponsors and CROsto design, manage, and execute patient-centric clinical trials with high dataquality, operational efficiency, and regulatory confidence. Learn more at www.obviohealth.com.

About Novotech

Novotech is a globally recognized full-service clinicalresearch organization (CRO) and scientific advisory partner for biotech andsmall- to mid-sized pharmaceutical companies seeking to advance drugdevelopment. With deep therapeutic and regulatory expertise and an expansiveglobal footprint across the Asia-Pacific region, North America, and Europe,Novotech offers clients an accelerated path to bring life-changing therapies tomarket.  Learn more at www.novotech-cro.com.